Comparison of equivalence of two different drug product interms of absorption, distribution, metabolism & excretion in healthy adult human subjects
- Registration Number
- CTRI/2024/02/062604
- Lead Sponsor
- BDR Pharmaceuticals Internationals Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Normal healthy adult human subjects of age between 18-45 years and Body Mass Index (BMI) ranges between 18.50 kg/m2 to 29.99 kg/m2
Subjects who have no evidence of underlying disease during screening and and check-in and whose screening is performed within 21 days of check in
Subjects whose screening laboratory values are within normal limits or considered by the physician or principal/clinical investigator
Generally healthy as documented by 12-lead electrocardiogram (ECG) Chest X-Ray and clinical laboratory assessments
Willing to consume Ovo lacto-vegetarian diet
Willing to comply to all requirements of this study protocol as well as instructed by the study personnel
Generally healthy as documented by gynaecological examination and breast examination (for female subjects – period I only)
Females of childbearing potential must have a negative serum pregnancy test performed within 21 days prior to initiation of the study & a negative urine pregnancy test prior to check-in of each period
Evidence of allergy or known hypersensitivity to Tucatinib or its inactive ingredients
Subjects with hepatic encephalopathy cholestasis myasthenia pre-existing liver disease alcohol abuse existing tinnitus and pre-existing gallbladder disease
Any major illness in the last three months or any significant ongoing chronic medical illness
Renal or liver impairment
History of alcohol addiction or abuse
Consumption of alcohol and its products grapefruit and or its juice and poppy containing foods within 48.00 hours prior to clinic admission and throughout the entire study
Subjects who have taken any prescription medications within 14 days prior to study check-in and throughout the study and any over the counter medicinal products herbal medications within 07 days prior to study check-in and throughout the study
Subject who had participated in any other study within the 90 days of check-in
History of difficulty in swallowing
History of difficulty in accessibility of veins
Positive results for urine screen of drugs of abuse (Marijuana-THC amphetamine-AMP barbiturates-BAR cocaine-COC benzodiazepines-BZD and morphine-MOR) in urine prior to check-in of this study period
Positive results for alcohol test prior to check-in of each period
Female subjects demonstrating a positive pregnancy screen
Female subjects who are currently lactating
Study & Design
- Study Type
- BA/BE
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method